HK1079448A1 - Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) - Google Patents

Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)

Info

Publication number
HK1079448A1
HK1079448A1 HK05111660.1A HK05111660A HK1079448A1 HK 1079448 A1 HK1079448 A1 HK 1079448A1 HK 05111660 A HK05111660 A HK 05111660A HK 1079448 A1 HK1079448 A1 HK 1079448A1
Authority
HK
Hong Kong
Prior art keywords
active principle
modified release
microcapsules
pharmaceutical formulation
aqueous suspension
Prior art date
Application number
HK05111660.1A
Other languages
English (en)
Inventor
Catherine Castan
Florence Guimberteau
Remi Meyrueix
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0210847A external-priority patent/FR2843881B1/fr
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Publication of HK1079448A1 publication Critical patent/HK1079448A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
HK05111660.1A 2002-04-09 2005-12-17 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) HK1079448A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0204409 2002-04-09
FR0210847A FR2843881B1 (fr) 2002-09-02 2002-09-02 Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
PCT/FR2003/001096 WO2003084518A2 (fr) 2002-04-09 2003-04-07 Suspension orale de microcapsules de principes actifs

Publications (1)

Publication Number Publication Date
HK1079448A1 true HK1079448A1 (en) 2006-04-07

Family

ID=28793279

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111660.1A HK1079448A1 (en) 2002-04-09 2005-12-17 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)

Country Status (16)

Country Link
US (5) US7906145B2 (es)
EP (1) EP1492511B3 (es)
JP (1) JP4732696B2 (es)
KR (1) KR101061351B1 (es)
CN (1) CN100553625C (es)
AT (1) ATE419840T1 (es)
AU (1) AU2003246792B2 (es)
BR (1) BRPI0309142C1 (es)
CA (1) CA2480826C (es)
DE (1) DE60325709D1 (es)
ES (1) ES2320438T7 (es)
HK (1) HK1079448A1 (es)
IL (2) IL164222A0 (es)
MX (1) MXPA04009968A (es)
PT (1) PT1492511E (es)
WO (1) WO2003084518A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
FR2841140B1 (fr) * 2002-06-24 2004-10-01 Servier Lab Microcapsules pour la liberation retardee et controlee du perindopril
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
JP2008530185A (ja) * 2005-02-21 2008-08-07 フラメル・テクノロジー ロサルタンの経口医薬剤形態
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
BRPI0609910A2 (pt) * 2005-05-10 2010-05-11 Novartis Ag composições farmacêuticas de famciclovir de liberação modificada
WO2007022105A2 (en) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
CN101400343B (zh) 2006-03-16 2012-01-11 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
US20090111736A1 (en) * 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
CA2782285A1 (en) * 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
EP2515882A2 (en) * 2009-12-22 2012-10-31 Abbot Healthcare Private Limited Controlled release pharmaceutical composition
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9254281B2 (en) * 2011-09-12 2016-02-09 Wright State University Composition and method for the treatment of neurodegeneration
CN102579398A (zh) * 2011-12-31 2012-07-18 沈阳药科大学 一种具有掩盖药物不良口味作用的肠溶微囊及制备方法
CN102552163B (zh) * 2012-01-05 2013-12-04 金陵药业股份有限公司 一种酒石酸美托洛尔缓释微丸及其制备方法
EP2884961B1 (en) 2012-08-15 2019-03-06 Tris Pharma Inc. Methylphenidate extended release chewable tablet
CA2988431C (en) 2013-03-12 2020-02-11 Panacea Biomatx, Inc. Method and system for making customized formulations for individuals
CA2947528C (en) 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
EP3137057B1 (en) * 2014-05-01 2020-09-09 Sun Pharmaceutical Industries Ltd Extended release liquid compositions of metformin
US20180104197A9 (en) * 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
JP6335692B2 (ja) * 2014-07-08 2018-05-30 ライオン株式会社 液体経口製剤
RU2017106010A (ru) 2014-07-30 2018-08-28 Сан Фармасьютикал Индастриз Лимитед Двухкамерная упаковка
JP2017524053A (ja) * 2014-08-15 2017-08-24 ダウ グローバル テクノロジーズ エルエルシー エチルセルロース分散体及び粉末
MA41124A (fr) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
MA43132A (fr) * 2015-10-30 2018-09-05 Cmp Dev Llc Compositions aqueuses de spironolactone
US10493083B2 (en) * 2015-10-30 2019-12-03 Cmp Development Llc Spironolactone aqueous compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
KR102393596B1 (ko) 2016-04-22 2022-05-04 리셉터 홀딩스, 인크. 속효성 식물-계 의약 화합물 및 영양 보충제
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US20220133647A1 (en) * 2019-03-01 2022-05-05 Avadel Legacy Pharmaceuticals, Llc Liquid guaifenesin compositions with stable extended release profiles
US20210275461A1 (en) 2019-09-12 2021-09-09 Nulixir Inc. Particles for administration of active ingredients and methods of making the same
CN112370437B (zh) * 2020-10-20 2022-10-21 好医生药业集团有限公司 一种阿莫西林胶囊及其制备方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029884A (en) 1971-03-18 1977-06-14 Abbott Laboratories Adenosine-5'-carboxylic acid amides
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
US3927216A (en) 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3914415A (en) 1973-06-14 1975-10-21 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US3914414A (en) 1973-06-14 1975-10-21 Abbott Lab Method of increasing coronary pO{HD 2 {B in mammals
US3892769A (en) 1973-07-20 1975-07-01 Merck & Co Inc Acetaminophen esters of aryl salicylic acids
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2417465A1 (de) 1974-04-10 1975-10-30 Lester R Wellman Vorrichtung zum oeffnen und wiederverschliessen eines dicht verschlossenen flexiblen behaelters
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
FR2313915A1 (fr) 1976-01-26 1977-01-07 Corneille Gilbert Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4308251A (en) 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
JPS6056122B2 (ja) 1980-05-21 1985-12-09 塩野義製薬株式会社 徐放性製剤
US4321253A (en) 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4454309A (en) 1980-11-12 1984-06-12 Tyndale Plains-Hunter, Ltd. Polyurethane polyene compositions
JPS57197214A (en) 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4507276A (en) 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
US4461759A (en) 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
HU187215B (en) 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4833905A (en) 1983-06-03 1989-05-30 Micromatic Textron Inc. Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
ATE60340T1 (de) 1984-10-19 1991-02-15 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
EP0198769A3 (en) 1985-04-12 1987-09-02 Forest Laboratories, Inc. Floating sustained release therapeutic compositions
EP0202027A1 (en) 1985-04-18 1986-11-20 Sumitomo Chemical Company, Limited A herbicidal composition
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
LU85943A1 (fr) 1985-06-12 1987-01-13 Galephar Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation
IT1185177B (it) * 1985-07-03 1987-11-04 Metalvuoto Films Spa Dispositivo per realizzare film plastici metallizzati presentanti zone ben delimitate prive di metallizzazione
US5002551A (en) 1985-08-22 1991-03-26 Johnson & Johnson Medical, Inc. Method and material for prevention of surgical adhesions
US4693896A (en) 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
SE8601624D0 (sv) 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
WO1987007833A1 (en) 1986-06-20 1987-12-30 Shacknai Jonah Oral sustained release medicament
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
IT1200217B (it) 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
SE8605515D0 (sv) 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a pharmaceutically active substance
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2061623T3 (es) 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4902513A (en) * 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US4961932A (en) 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
DE3810757A1 (de) 1988-03-30 1989-10-26 Freudenberg Carl Fa Verfahren zur herstellung einer mikroporoesen folie
US5268182A (en) 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
US5028434A (en) 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
IT1226940B (it) * 1988-09-16 1991-02-22 Recordati Chem Pharm Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide
FI894611A (fi) 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutiska preparat.
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
IT1227899B (it) * 1988-12-23 1991-05-14 Poli Ind Chimica Spa Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
FR2642080B1 (fr) 1989-01-23 1992-10-02 Onera (Off Nat Aerospatiale) Polysilanes et leur procede de preparation
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
AU632602B2 (en) 1989-08-02 1993-01-07 John David Arnold Method and preparation for reducing risk of myocardial infarction
NZ233975A (en) 1989-08-16 1992-06-25 Sterling Drug Inc Aspirin granules coated with a gastroprotectant
IT1256651B (it) 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
AU634606B2 (en) 1989-11-06 1993-02-25 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5248516A (en) 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
GB9002495D0 (en) 1990-02-05 1990-04-04 Monsanto Europe Sa Glyphosate compositions
US5206030A (en) 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
WO1991019486A1 (en) 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
CA2083606C (en) 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
WO1992001446A1 (en) 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
SE9002684D0 (sv) 1990-08-17 1990-08-17 Malvac Foundation C O Peter Pe New peptides and their use
EP0477135A1 (en) 1990-09-07 1992-03-25 Warner-Lambert Company Chewable spheroidal coated microcapsules and methods for preparing same
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5219895A (en) 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
FI922107A0 (fi) 1991-05-10 1992-05-08 Faulding F H & Co Ltd Mikrokapselkomposition och foerfarande.
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
DE69220317T2 (de) 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5409709A (en) 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
IL103224A (en) 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
WO1994009762A1 (en) 1992-11-05 1994-05-11 Merck & Co., Inc. Drug delivery device
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
FR2708932B1 (fr) 1993-08-10 1995-11-10 Flamel Tech Sa Procédé de préparation de polyaminoacides.
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
MX9605419A (es) 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
FR2724563A1 (fr) 1994-09-15 1996-03-22 Coletica Utilisation de membranes collageniques comme protheses de regeneration peritoneale
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
FR2732218B1 (fr) 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
US5750468A (en) 1995-04-10 1998-05-12 Monsanto Company Glyphosate formulations containing etheramine surfactants
US5674529A (en) 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
DE69636413T2 (de) 1995-11-13 2007-03-29 North West University Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
CA2238975A1 (en) 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
FR2746035B1 (fr) 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
DE19628341C2 (de) * 1996-07-13 1998-09-17 Sihl Gmbh Aufzeichnungsmaterial für Tintenstrahlverfahren mit wäßriger Tinte und Verwendung zum Herstellen wasserfester und lichtbeständiger Aufzeichnungen auf diesem Material
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
AU5101798A (en) 1996-12-04 1998-06-29 Bristol-Myers Squibb Company Method for oral administration of buspirone
WO1998026803A1 (fr) 1996-12-19 1998-06-25 Daiichi Pharmaceutical Co., Ltd. Composition pharmaceutique pour administration par voie orale
FR2759083B1 (fr) 1997-02-06 1999-04-30 Dev Des Utilisations Du Collag Materiau collagenique utile notamment pour la prevention d'adherences post-operatoires
US5981761A (en) 1997-03-27 1999-11-09 Solutia Inc. Crosslinked polyaspartate salts a process for their production
US6162463A (en) 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
WO1998053680A1 (en) 1997-05-30 1998-12-03 Monsanto Company Process and compositions promoting biological effectiveness of exogenous chemical substances in plants
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
JP3677156B2 (ja) 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
WO1999013864A2 (en) 1997-09-19 1999-03-25 Shire Laboratories, Inc. Solid solution beadlet
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
FR2771291B1 (fr) 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
US6444246B1 (en) 1997-12-16 2002-09-03 Mccormick & Company, Inc. Cake-resistant, hygroscopically sensitive materials and process for producing the same
BR9813826A (pt) 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
NZ506202A (en) 1998-03-19 2003-10-31 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method
YU51300A (sh) 1998-03-20 2002-09-19 Cowa Co. Ltd. Adhezivna farmaceutska kompozicija za želudac i/ili dvanaestopalačno crevo
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
IL138765A0 (en) 1998-03-30 2001-10-31 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
DK0974356T3 (da) 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
CA2338780C (en) 1998-07-28 2007-01-02 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing medicinal substance at targeted site in intestine
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
US6179862B1 (en) 1998-08-14 2001-01-30 Incept Llc Methods and apparatus for in situ formation of hydrogels
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
JP2000128774A (ja) 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
WO2000025752A1 (en) 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
NZ511614A (en) 1998-11-12 2003-12-19 Smithkline Beecham P Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19860698A1 (de) 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
JP3645816B2 (ja) 1999-02-23 2005-05-11 ユハン・コーポレーション ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
AU767177B2 (en) 1999-04-13 2003-11-06 Beecham Pharmaceuticals (Pte) Limited Novel method of treatment
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001008661A2 (en) 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
NZ517559A (en) * 1999-08-31 2004-08-27 Gruenenthal Chemie Sustained release pharmaceutical composition containing tramadol saccharinate
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
HU229352B1 (en) 1999-11-03 2013-11-28 Bristol Myers Squibb Co Medicament comprising the combination of metformin and glyburide
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
AU2001232020A1 (en) 2000-02-09 2001-08-20 West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited Floating drug delivery composition
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6951534B2 (en) 2000-06-13 2005-10-04 Acorn Cardiovascular, Inc. Cardiac support device
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
JP2002003366A (ja) 2000-06-23 2002-01-09 Freunt Ind Co Ltd 固形薬剤用水系コーティング剤組成物
KR100496749B1 (ko) 2000-07-05 2005-06-22 아사히 가세이 가부시키가이샤 셀룰로스 분말
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US6499158B1 (en) 2000-10-30 2002-12-31 Steris, Inc. Surgical table top and accessory clamp used thereon
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
ATE425731T1 (de) 2000-12-28 2009-04-15 Tap Pharmaceutical Prod Inc Pharmazeutische zusammensetzungen eines nichtmagensaftresistenten protonenpumpen-hemmers mit einer carbonat- und bicarbonatsalzkombination
AU2002257582A1 (en) 2001-02-14 2002-09-04 Glaxo Wellcome S.A. Pharmaceutical formulation
CA2440069A1 (en) * 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
FR2821745B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
BR0102252B1 (pt) 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
WO2002085335A1 (en) 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
GB0114532D0 (en) 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
IL160217A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Compositions and methods to prevent abuse of opioids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1418886A1 (de) 2001-08-10 2004-05-19 Beiersdorf AG Kosmetische reinigungsrezepturen auf basis einer kombination von natriumlaurethsulfat und alkylpolyamphopolycarboxyglycinaten
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
FR2830447B1 (fr) 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
GB0124459D0 (en) 2001-10-11 2001-12-05 Novartis Ag Organic compounds
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
FR2837100B1 (fr) 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
WO2003080069A1 (en) 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
US7790215B2 (en) 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
WO2003084517A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
WO2003094899A1 (es) 2002-05-09 2003-11-20 Diffucap-Chemobras Química E Farmacéutica, Ltda. Nuevo procedimiento para la preparacion de composiciones de liberacion programada conteniendo (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, y al producto obtenido por dicho procedimiento
AU2003229005A1 (en) 2002-05-10 2003-11-11 Merck And Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
AU2003245345A1 (en) 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
NZ520149A (en) 2002-07-12 2003-01-31 Reinforced Concrete Pipes Pty Anchoring device
US20040208936A1 (en) 2002-07-22 2004-10-21 Roland Chorin Novel compositions
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2843117B1 (fr) 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US6727839B2 (en) 2002-08-23 2004-04-27 Broadcom Corporation High speed, low power comparator
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
JP5189242B2 (ja) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
JP2004188307A (ja) 2002-12-11 2004-07-08 Japan Atom Energy Res Inst リン酸基を有するジルコニウム担持繊維状吸着材の合成方法、及びそれを用いたヒ素の除去
BR0317275A (pt) 2002-12-11 2005-11-08 Pfizer Prod Inc Liberação controlada de uma substância ativa em um ambiente de gordura alta
JP4865330B2 (ja) 2002-12-13 2012-02-01 デュレクト コーポレーション 経口ドラッグデリバリーシステム
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20060210620A1 (en) 2003-01-21 2006-09-21 Kumra Pannanchukunnath M Co-precipitated amorphous losartan and dosage forms comprising the same
WO2004087175A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
PT2279729T (pt) 2003-07-17 2016-09-22 Banner Life Sciences Llc Preparações de libertação controlada
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
NZ545202A (en) 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
ZA200601181B (en) 2003-08-13 2007-04-25 Smith Howard J & Ass Pty Ltd Method of treating viral infections
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AU2005259478B2 (en) 2004-07-01 2010-07-15 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
PL1811979T3 (pl) 2004-09-27 2009-04-30 Sigmoid Pharma Ltd Mikrokapsułki zawierające metyloksantynę i kortykosteroid
CA2581002C (en) 2004-10-15 2012-01-10 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
FR2878161B1 (fr) 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
FR2878158B1 (fr) 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
FR2889810A1 (fr) 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US20070166378A1 (en) * 2005-06-09 2007-07-19 Flamel Technologies, Inc. Oral ribavirin pharmaceutical compositions
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
FR2892937B1 (fr) 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form

Also Published As

Publication number Publication date
US20170281558A1 (en) 2017-10-05
JP4732696B2 (ja) 2011-07-27
WO2003084518A3 (fr) 2004-04-01
US20150374635A1 (en) 2015-12-31
PT1492511E (pt) 2009-04-09
WO2003084518A2 (fr) 2003-10-16
CN100553625C (zh) 2009-10-28
EP1492511A2 (fr) 2005-01-05
ATE419840T1 (de) 2009-01-15
US20060165807A1 (en) 2006-07-27
KR20050005438A (ko) 2005-01-13
AU2003246792B2 (en) 2008-08-28
ES2320438T3 (es) 2009-05-22
EP1492511B3 (fr) 2012-05-02
US20150374636A1 (en) 2015-12-31
US10004693B2 (en) 2018-06-26
BR0309142A (pt) 2005-02-01
ES2320438T7 (es) 2013-02-14
CA2480826A1 (fr) 2003-10-16
IL164222A (en) 2011-07-31
US20110117205A1 (en) 2011-05-19
EP1492511B1 (fr) 2009-01-07
MXPA04009968A (es) 2004-12-13
BRPI0309142C1 (pt) 2021-05-25
CA2480826C (fr) 2012-02-07
BRPI0309142B1 (pt) 2015-09-22
US9814684B2 (en) 2017-11-14
US7906145B2 (en) 2011-03-15
JP2005527573A (ja) 2005-09-15
AU2003246792A1 (en) 2003-10-20
KR101061351B1 (ko) 2011-08-31
BRPI0309142B8 (pt) 2016-09-13
IL164222A0 (en) 2005-12-18
CN1652755A (zh) 2005-08-10
DE60325709D1 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
HK1079448A1 (en) Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
IL164221A0 (en) Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO1999059544A3 (en) Orally disintegrable tablets
WO2007016352A3 (en) Oral liquid losartan compositions
UA93530C2 (ru) Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2008099615A1 (ja) 微粒子油性懸濁液を含む医薬組成物
WO2005053727A3 (en) Pharmaceutical compositions for bioactive peptide agents
SI2018153T1 (sl) Tekoči oralni sestavki
HRP20100363T1 (hr) Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom
IL174691A0 (en) Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient
WO2002015880A8 (en) Powdered mannitol and mannitol-containing compositions
WO2009044380A3 (en) Formulations containing orlistat particles having controlled particle size
WO2007128495A3 (en) Solid pharmaceutical composition of gabapentin
JP2006527741A5 (es)
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
EP1123695A3 (en) Oral composition comprising capsules containing keratin
AU2003202550A1 (en) Pharmaceutical formulations with modified release
FR2843301B1 (fr) Forme galenique pour la delivrance colique de principes actifs
WO2008122425A3 (en) Oral compositions containing tacrolimus in amorphous form

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140407